CYRAMZA (ramucirumab) is a fully human monoclonal antibody that functions as a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist. By selectively binding to VEGFR2, CYRAMZA inhibits ligand-induced receptor activation, thereby blocking angiogenesis, a critical process in tumor growth and metastasis. This targeted mechanism underpins its clinical utility across multiple solid tumor types.
Approved for intravenous administration, CYRAMZA is utilized either as monotherapy or in combination with established chemotherapeutic regimens, depending on the cancer type and line of therapy. Its clinical application is supported by robust evidence from multiple phase III trials, demonstrating efficacy in improving outcomes for patients with advanced gastric, lung, colorectal, and liver cancers. The safety profile and dosing recommendations are tailored to each indication, with careful monitoring for specific adverse events such as hypertension, proteinuria, and hemorrhagic complications.
